Combination effect of levofloxacin and cefmenoxime against ocular isolates of Pseudomonas aeruginosa.
Keratitis
Ocular infection
Synergy
Tolerance
Journal
Contact lens & anterior eye : the journal of the British Contact Lens Association
ISSN: 1476-5411
Titre abrégé: Cont Lens Anterior Eye
Pays: England
ID NLM: 9712714
Informations de publication
Date de publication:
20 Sep 2024
20 Sep 2024
Historique:
received:
12
08
2024
revised:
11
09
2024
accepted:
12
09
2024
medline:
22
9
2024
pubmed:
22
9
2024
entrez:
21
9
2024
Statut:
aheadofprint
Résumé
This study aimed to investigate the effects of the combination of levofloxacin (LVFX) and cefmenoxime (CMX) on ocular isolates of Pseudomonas aeruginosa. Twenty-three strains of P. aeruginosa isolated from microbial keratitis cases in Australia were utilized in this study. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of each antibiotic alone were determined and the combined susceptibility of antibiotics was assessed through fractional inhibitory concentration index (FICI). Additionally, tolerance of a ciprofloxacin tolerant P. aeruginosa isolate to each antibiotic alone and combination were analyzed. The median MIC and MBC values of CMX against P. aeruginosa were 16 µg/mL and 32 µg/mL, respectively. The median MIC and MBC values of LVFX were 0.5 µg/mL and 1 µg/mL, respectively, and all isolates were susceptible. In dual combination, the median of FICI of all strains was 0.63; seven strains showed synergistic effects (FICI≤0.5), and fifteen strains showed additive activities, while no strains exhibited antagonism. The isolate of P. aeruginosa that had previously exhibited tolerance to ciprofloxacin showed high tolerance to CMX alone and low tolerance to LVFX alone. This strain showed low tolerance to the combination of CMX and LVFX. The combination of LVFX with CMX may have beneficial interactions which increase antibacterial activity against P. aeruginosa isolates and may be a feasible option for addressing the issue of bacteria resistant to each antibiotic.
Identifiants
pubmed: 39306575
pii: S1367-0484(24)00204-2
doi: 10.1016/j.clae.2024.102311
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102311Informations de copyright
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.